Core Viewpoint - The "Global Traditional Chinese Medicine Culture Gala" held in Beijing emphasizes the global recognition and innovative spirit of traditional Chinese medicine (TCM), showcasing its integration with modern technology and health concepts [1][3]. Group 1: Event Overview - The event was co-hosted by Phoenix TV and Dong'e Ejiao, celebrating the ancient wisdom of TCM and its journey onto the global stage [1]. - The gala featured tributes to five individuals who have made significant contributions to the international dissemination and cross-disciplinary integration of TCM [5]. Group 2: Recognition of Contributors - The first honoree, Dr. Ehsan Doustmohammadi from Iran, translated over twenty Chinese classics into Persian, including the "Huangdi Neijing," to enhance understanding of Chinese culture in Iran [5][7]. - The second honoree, Malaysian TCM practitioner Liang Jiarin, innovatively uses space concepts to teach TCM, making it appealing to younger generations [9]. - The third honoree, Dr. Li Zong'en from Silicon Valley, applies AI and big data to systematize TCM practices, aiming to validate traditional knowledge through modern scientific methods [11]. - The fourth honoree, Valeria from Italy, has been practicing TCM for over twenty years, using music to create a calming environment for patients [13]. - The final honoree, Dr. Diallo from Mali, has trained over a thousand local healthcare workers in TCM techniques, serving more than 120,000 patients in Africa [15]. Group 3: Future Initiatives - Following the tribute segment, the second season of "Four Seas TCM" was launched, aiming to document more global TCM stories and foster cross-cultural dialogue [17].

Core Insights - Shandong Buchang Pharmaceutical Co., Ltd. reported a revenue of 11.006 billion yuan for 2024, with a first-quarter revenue of 2.785 billion yuan in 2025, reflecting a year-on-year increase of 5.47% [1] - The company has maintained a growth trajectory in R&D investment, reaching approximately 717 million yuan in 2024, a year-on-year increase of 8.58%, ranking fourth in the traditional Chinese medicine industry [2] - Buchang Pharmaceutical has made significant strides in internationalization, with its core product, Naoxin Tong capsule, successfully registered in Hong Kong and other products approved in Malaysia, Canada, Kazakhstan, and Uzbekistan [2] Financial Performance - The company's net profit attributable to shareholders for the first quarter of 2025 was 307 million yuan, a year-on-year increase of 169.49%, while the non-net profit was 300 million yuan, up 197.05% year-on-year [1] - Since its listing in 2016, the company has paid over 7.5 billion yuan in cash dividends and repurchased nearly 1.8 billion yuan worth of shares, demonstrating a strong commitment to shareholder returns [6] R&D and Innovation - In 2024, Buchang Pharmaceutical applied for 35 new patents and successfully obtained 27 patents, including 9 invention patents, showcasing its commitment to innovation [4] - The company has adopted an "AI + Traditional Chinese Medicine" research and development model to enhance drug development efficiency and product quality control [4] - The "Brain-Heart Treatment" theory proposed by the company has been included in the National Health Commission's "13th Five-Year Plan" textbook, marking a significant theoretical contribution [4] Market Position and Strategy - Buchang Pharmaceutical holds a leading position in the cardiovascular traditional Chinese medicine market, with its three major products generating a combined revenue of 5.83 billion yuan in 2024 [2] - The company has a total of 468 valid patents and 213 products under research, covering major disease treatment areas, which strengthens its competitive edge [3] - The company is strategically expanding into biopharmaceuticals and vaccines, aligning with national policies that support the pharmaceutical industry [4][5] Social Responsibility and Brand Image - Buchang Pharmaceutical has contributed nearly 32 billion yuan in taxes since its establishment, reflecting its commitment to corporate social responsibility [6] - The company's "Together, Build China's Heart" charity project has provided medical assistance to 2 million people, enhancing its brand image and social influence [7] Future Outlook - The company plans to expand its product coverage to include major disease areas such as gynecology, urology, diabetes, malignant tumors, digestive, and respiratory systems, while leveraging its traditional advantages in Chinese medicine [8] - With the ongoing globalization of traditional Chinese medicine and the Belt and Road Initiative, Buchang Pharmaceutical is well-positioned to capitalize on international market opportunities [7][8]